Femara 1st Aromatase Inhibitor To Indicate Overall Survival Benefit Versus Tamoxifen
 

Femara showed reduced risk of death by 13% (P=0.08) versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the study period, following the study's unblinding - In a separate censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was 19% (HR= 0.81, 95% CI: 0.69-0.

More...